High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$69.7M
$69,650,457
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
CFO
Sell to Cover
|
2026-03-06 | $853,993x12 | S | Form 4 |
|
MDGL
S
MADRIGAL PHARMACEUTICALS, INC.
Huntsman Carole
• Officer • Chief Commercial Officer
Sell to Cover
2026-03-06
$180,983
|
||||||
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Officer • Chief Commercial Officer
Sell to Cover
|
2026-03-06 | $180,983 | S | Form 4 |
|
MDGL
S
MADRIGAL PHARMACEUTICALS, INC.
Kelley Shannon T
• Officer • General Counsel
Sell to Cover
2026-03-06
$155,498
|
||||||
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Officer • General Counsel
Sell to Cover
|
2026-03-06 | $155,498 | S | Form 4 |
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
CEO
Sell to Cover
|
2026-03-06 | $718,316 | S | Form 4 |
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Director
Sell to Cover
|
2026-03-06 | $212,083 | S | Form 4 |
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
CFO
Sell to CoverΔOwn -11.3%
|
2026-03-02 | $505,389 | S | Form 4 |
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Director
Other
|
2026-02-23 | $18,400 | M | Form 4 |
|
MDGL
S
MADRIGAL PHARMACEUTICALS, INC.
Huntsman Carole
• Officer • Chief Commercial Officer
Sell to Cover
2026-01-26
$449,339x2
|
||||||
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Officer • Chief Commercial Officer
Sell to Cover
|
2026-01-26 | $449,339x2 | S | Form 4 |
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Director
Other
|
2026-01-26 | $65,840 | M | Form 4 |
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
CEO
Sell to Cover
|
2026-01-26 | $776,546 | S | Form 4 |
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Director
Sell to Cover
|
2026-01-26 | $318,596 | S | Form 4 |
|
MDGL
S
MADRIGAL PHARMACEUTICALS, INC.
Kelley Shannon T
• Officer • General Counsel
Sell to Cover
2026-01-20
$344,173x2
|
||||||
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Officer • General Counsel
Sell to Cover
|
2026-01-20 | $344,173x2 | S | Form 4 |
|
MDGL
S
MADRIGAL PHARMACEUTICALS, INC.
Taub Rebecca
• Director
Sell to Cover
2026-01-20
$1,098,343Large
|
||||||
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Director
Sell to Cover
|
2026-01-20 | $1,098,343Large | S | Form 4 |
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Director
Other
|
2026-01-09 | $391,840x2 | M | Form 4 |
|
MDGL
S
MADRIGAL PHARMACEUTICALS, INC.
FRIEDMAN PAUL A
• Director
10b5-1 Sell
2026-01-09
$12,963,305MEGAx29
|
||||||
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Director
10b5-1 Sell
|
2026-01-09 | $12,963,305MEGAx29 | S | Form 4 |
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Director
Other
|
2026-01-09 | $294,670x2 | M | Form 4 |
|
MDGL
S
MADRIGAL PHARMACEUTICALS, INC.
Taub Rebecca
• Director
10b5-1 Sell
2026-01-09
$9,749,392Whalex30
|
||||||
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Director
10b5-1 Sell
|
2026-01-09 | $9,749,392Whalex30 | S | Form 4 |
|
MDGL
M
MADRIGAL PHARMACEUTICALS, INC.
FRIEDMAN PAUL A
• Director
Equity Compensation
2025-12-10
$391,840x2
|
||||||
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Director
Equity Compensation
|
2025-12-10 | $391,840x2 | M | Form 4 |
|
MDGL
S
MADRIGAL PHARMACEUTICALS, INC.
FRIEDMAN PAUL A
• Director
10b5-1 Sell
2025-12-10
$13,694,158MEGAx9
|
||||||
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Director
10b5-1 Sell
|
2025-12-10 | $13,694,158MEGAx9 | S | Form 4 |
|
MDGL
M
MADRIGAL PHARMACEUTICALS, INC.
Taub Rebecca
• Director
Equity Compensation
2025-12-10
$294,670x2
|
||||||
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Director
Equity Compensation
|
2025-12-10 | $294,670x2 | M | Form 4 |
|
MDGL
S
MADRIGAL PHARMACEUTICALS, INC.
Taub Rebecca
• Director
10b5-1 Sell
2025-12-10
$10,297,573MEGAx9
|
||||||
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Director
10b5-1 Sell
|
2025-12-10 | $10,297,573MEGAx9 | S | Form 4 |
|
MDGL
S
MADRIGAL PHARMACEUTICALS, INC.
Sibold William John
• CEO
Sell to Cover
2025-12-04
$1,380,816Large
|
||||||
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
CEO
Sell to Cover
|
2025-12-04 | $1,380,816Large | S | Form 4 |
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
CEO
Equity Compensation
|
2025-12-03 | $0 | M | Form 4 |
|
MDGL
M
MADRIGAL PHARMACEUTICALS, INC.
Dier Mardi
• CFO
Equity Compensation
2025-12-02
$1,050,052Largex2
|
||||||
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
CFO
Equity Compensation
|
2025-12-02 | $1,050,052Largex2 | M | Form 4 |
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
CFO
10b5-1 Sell
|
2025-12-02 | $2,413,416Largex15 | S | Form 4 |
|
MDGL
S
MADRIGAL PHARMACEUTICALS, INC.
Huntsman Carole
• Officer • Chief Commercial Officer
Sell to Cover
2025-11-21
$1,082,986Largex11
|
||||||
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Officer • Chief Commercial Officer
Sell to Cover
|
2025-11-21 | $1,082,986Largex11 | S | Form 4 |
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Director
Other
|
2025-11-13 | $117,160x2 | M | Form 4 |
|
MDGL
S
MADRIGAL PHARMACEUTICALS, INC.
Levy Richard S
• Director
10b5-1 Sell
2025-11-13
$4,428,198Largex14
|
||||||
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Director
10b5-1 Sell
|
2025-11-13 | $4,428,198Largex14 | S | Form 4 |
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Director
Other
|
2025-11-05 | $3,399,036Largex3 | M | Form 4 |
|
MDGL
S
MADRIGAL PHARMACEUTICALS, INC.
BATE KENNETH
• Director
Discretionary Sell
2025-11-05
$8,027,354Whalex11
|
||||||
| MDGL |
MADRIGAL PHARMACEUTICALS, INC.
|
Director
Discretionary Sell
|
2025-11-05 | $8,027,354Whalex11 | S | Form 4 |